Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–56.
Google Scholar
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–80.
Google Scholar
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e876-94.
Google Scholar
Barrera-Chimal J, Bonnard B, Jaisser F. Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases. Annu Rev Physiol. 2022;84:585–610.
Google Scholar
Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–61.
Google Scholar
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018;6:461.
Google Scholar
Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014;16:414.
Google Scholar
Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, et al. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24:489.
Google Scholar
Obeid H, Chen Cardenas SM, Khairi S, Turcu AF. Personalized treatment of patients with primary aldosteronism. Endocr Pract. 2023;29:484–90.
Google Scholar
Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179:3220–34.
Google Scholar
Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist. Front Cardiovasc Med. 2024;11:1476029.
Google Scholar
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Randomized aldactone evaluation study investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.
Google Scholar
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
Google Scholar
Zhu Y, Song M, Chen T, Yang Z, Liu Y. Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials. Int Urol Nephrol. 2023;55:1373–81.
Google Scholar
Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475–85.
Google Scholar
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.
Google Scholar
Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish heart failure registry. Eur J Heart Fail. 2018;20:1326–34.
Google Scholar
Zahir D, Bonde A, Madelaire C, Malmborg M, Butt JH, Fosbol E, et al. Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017. Eur J Heart Fail. 2022;24:539–47.
Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Google Scholar
Higgins JPTJ, Chandler J, Cumpston M, Li T, Page M. Cochrane handbook for systematic reviews of interventions. Altman DG, editor: Cochrane Training;: Deeks JJ HJ; 2024.
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.
Google Scholar
Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15:112.
Google Scholar
Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492–5.
Google Scholar
Briere JB, Bowrin K, Millier A, Toumi M, Wojciechowski P, Taieb V. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. J Med Econ. 2019;22:760–5.
Google Scholar
Deeks JJHJ, Altman DG, McKenzie JE, Veroniki AA,Chapter 10: Chap. 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In:, Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 65 Cochrane, 2024 Available from cochraneorg/handbook.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
Google Scholar
Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, et al. Double-Blind, randomized, Placebo-Controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J. 2017;82:148–58.
Google Scholar
Khan LA, Jamil A, Greene SJ, Khan MS, Butler J. Aldosterone and potassium in heart failure: overcoming this major impediment in clinical practice. Card Fail Rev. 2024;10:e18.
Google Scholar
Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018;24:313–20.
Google Scholar
Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013;168:5135–42.
Google Scholar
Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schäfers HJ, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289:6656–68.
Google Scholar
Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324:488–504.
Google Scholar
Kondo T, Henderson AD, Docherty KF, Jhund PS, Vaduganathan M, Solomon SD, et al. Why have we not been able to demonstrate reduced mortality in patients with HFrEF/HFpEF?? J Am Coll Cardiol. 2024;84:2233–40.
Google Scholar
Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, Karic A. The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF. Med Arch. 2023;77:105–11.
Google Scholar
Pardo-Martínez P, Barge-Caballero E, Bouzas-Mosquera A, Barge-Caballero G, Couto-Mallón D, Paniagua-Martín MJ, et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. Eur J Intern Med. 2022;97:86–94.
Google Scholar
Vukadinović D, Lavall D, Vukadinović AN, Pitt B, Wagenpfeil S, Böhm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017;188:99–108.
Google Scholar
Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23:1698–707.
Google Scholar
Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, et al. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021;23:776–84.
Google Scholar
Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20:1217–26.
Google Scholar
Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30:3758–64.
Google Scholar
Memon AAQ, Iqbal S. Finerenone, a novel and safer approach toward management of diabetic kidney disease with heart failure. Global J Medical, Pharmaceutical, and Biomedical Update. 2022;17:12.
Google Scholar
Ashjian E, Clarke M, Pogue K. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health-Syst Pharm. 2023;80:1708–21.
Google Scholar
Gudino Flores, Paola MD; Rodriguez Salazar, Juan Diego MD; Nahar, Bryan Lester MD; Jim, Belinda MD. Finerenone: A Novel Third-Generation Mineralocorticoid Receptor Antagonist. Cardiology in Review. 2023. https://doi.org/10.1097/CRD.0000000000000573.
Yang P, Shen W, Chen X, Zhu D, Xu X, Wu T, et al. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Heart Fail Rev. 2019;24:637–46.
Google Scholar
Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, et al. Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation. 2025;151:45–58.
Google Scholar